Beverly Hills NORML Director Cheryl Shuman testifies

New Post Public Reply Private Reply Replies (0) Message Board
CherylShuman

Beverly Hills NORML Director Cheryl Shuman testifies on the cruelty of banning medical marijuana patients from transplant lists

  • by Russ Belville, NORML Outreach CoordinatorJanuary 23, 2010

    Recently the Los Angeles City Council held hearings on the thorny issue of medical marijuana dispensary regulation. For years city officials have abrogated their duty to create sensible regulations for the dispensaries that have proliferated across the Los Angeles basin. The number of dispensaries has ballooned to over 500 (not the 1,000+ often claimed) following an ineffective moratorium on the retail medical marijuana outlets.

    As usual, the hearings were packed, with medical marijuana patients and activists flooding the chambers to add their testimony to the record.  One citizen petitioning her government for a redress of grievances was the Executive Director of the new Beverly Hills NORML 90210, Cheryl Shuman.  In sixty seconds of testimony, Cheryl recounts her own personal medical marijuana tragedy, one that has befallen many desperately ill patients who use cannabis — even legally — and require life-saving organ transplants:

    Cheryl’s case is not unique.  All across America, hospitals are booting patients off of organ transplant lists because of their use of cannabis.  Being a legal user of cannabis for medicinal purposes in the now fourteen states that recognize that right is of no help; even legal medical marijuana patients are essentially given a death sentence by hospital and insurance bureaucracies for their use of a safe, non-toxic herbal remedy.

    Timothy Garon was a Seattle musician who had contracted Hepatitis C.  Garon was on a waiting list for a life-saving liver transplant.  The state of Washington recognizes Hep C as a qualifying condition for the medical use of cannabis.  Garon’s physician, Dr. Brad Roter, authorized Garon to smoke pot to alleviate his nausea and abdominal pain and to stimulate his appetite while he awaited.  Garon had become dangerously thin and malnourished and the cannabis therapy helped bring him back from the brink of death.

    But unbeknown to Dr. Roter, hospital transplant programs have strict rules that forbid “substance abusers” from qualifying for organ transplants.  Seattle’s University of Washington Medical Center told Garon that if he ceased his marijuana use and tested clean for 60 days, he could have his liver transplant.  Another medical center specified six months of marijuana abstinence before they’d save his life with surgery.

    Doctors had told Garon he had about two weeks to live and he died on May 1, 2008.  The cruelest irony is that cannabis is one of the few therapies Garon could have taken for pain and nausea that is not hepatoxic (liver-killing) and laden with a list of other nasty side effects.

    In Hawaii, Kimberley Reyes suffered from cirrhosis and hepatitis and was given thirty days to live.  She applied for and received approval for a life-saving liver transplant, only to have the rug pulled out from under her three days later when her insurance company, Hawaii Medical Service Association, discovered cannabis in her system, which she had used to relieve feelings of nausea, disorientation and pain.  Ten days later she, too, was dead.

    In Washington, Jonathan Simchen suffers from kidney failure. Doctors at Virginia Mason and University of Washington medical centers deny him a life-saving kidney transplant because of his participation in the Washington State medical marijuana program.  According to Alisha Mark, a spokeswoman for Virginia Mason, “any patient who smokes any product — tobacco, cloves, medical marijuana — would be precluded from receiving a transplant here.”

    In Georgia, a man named Walter emailed me after reading these transplant stories:

    My name is Walter and my kidney transplant was denied by Blue Cross Blue Shield of Georgia due to the fact I smoke marijuana.

    In January I went to the University of Minnesota/Fairview Transplant Center for an evaluation. In order to be completely honest with all the doctors I made them aware of the fact that I smoke marijuana and have for quite some time. I also made them aware that the use of marijuana has helped me with the decline of my appetite due to end stage of renal disease. With the exception of the hospital shrink, no one seemed to have a problem with it and even commented that my smoking had nothing to do with my kidney.

    Blue Cross Blue Shield approved the evaluation but [after] having received the paperwork from Minnesota has declined my transplant, stating “Kidney transplantation has not been shown to be more beneficial than other alternative treatments for patients with ongoing substance abuse. Thus, I recommended denial of kidney transplantation” (Ronald Hunt MD – Medical Director).

    Jim Klahr is a well-known medical marijuana activist here in Oregon who also suffers from cirrhosis and hepatitis C.  In an ironic twist, he sits on the state’s advisory committee on medical marijuana, yet hasn’t used his most effective medicine for his pain and nausea since 2004 because he’s terrified of losing his chance for a liver transplant.  “I’ve capitulated because basically I don’t have much of a choice,” says Klahr.  Paul Stanford of The Hemp & Cannabis Foundation, the state’s largest medical marijuana clinic, estimates at least 30 Oregonians who use medical weed have died in the past 10 years after hospitals denied them new organs.

    We understand why hospitals have strict qualifying criteria for transplant candidates.  Transplant organs are in high demand and doctors want every recipient to have the best chance at survival possible.  Hospitals screen their transplant lists for “substance abusers” because it really doesn’t make much sense to put a new liver into an alcoholic who will just go out and drink that organ into cirrhosis and failure as well.  It’s foolhardy to give a new kidney to a heroin addict who would then possibly share needles and come down with another life-threatening disease.

    But in the case of cannabis users, the concern for the chance of post-transplant survival is misplaced.  According to new research at the University of Michigan, cannabis use has no impact on the long-term survival rates of liver transplant recipients.  After studying 1,489 liver transplant patients, 155 of whom were cannabis users, over a span of eight years, researchers concluded, “Patients who did and did not use marijuana had similar survival rates. Current substance abuse policies do not seem to systematically expose marijuana users to additional risk of mortality.”

    The cases of Cheryl Shuman and all these victims of a cruel and needless discrimination against desperately ill cannabis consumers illustrate why existing medical marijuana laws, while commendable, do not go far enough.  Cheryl Shuman, Tim Garon, Jim Klahr and others are all legal medical marijuana patients in their state, yet powerless under the law to force hospitals to keep them on the transplant lists.  This discrimination exists because cannabis is considered an “illicit drug of abuse” in the same category as heroin and LSD.  This is why cannabis must be removed from Schedule I, legalized for prescription by any doctor in any state, so that it may truly be treated like other medicines, including the prohibition on discrimination against a transplant patient for the use of his or her doctor’s prescriptions.

CHERYL SHUMAN DUE DILIGENCE ::: PLEASE POST EVERYWHERE

Original Link: http://blog.norml.org/2010/01/23/beverly-hills-norml-director-cheryl-shuman-testifies-on-the-cruelty-of-banning-medical-marijuana-patients-from-transplant-lists/

Rapid Fire Marketing, Inc. (RFMK) Stock Research Links

RFMK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 67

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 455

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 0

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading

Top 5 Most Recently Viewed Articles

Hepsiburada's Recent Asset-Backed Securities Issuance Explained

Updated Category News Views 205

Hepsiburada's Second Issuance of Asset-Backed Securities Hepsiburada, a premier e-commerce platform based in Türkiye, has made headlines with its recent announcement regarding the second issuance of asset-backed securities amounting to TRY 350 million. This move marks a significant step as the company continues to solidify its position in the competitive online...

Continue Reading
Discover SODI's Aroma Scent Phone Case: A New Touch to Tech

Updated Category News Views 319

SODI Unveils Innovative Aroma Scent Phone Case SODI, a premium Apple accessories brand, has launched an exciting new product on Kickstarter that merges technology with emotional design: the Aroma Scent Phone Case. This innovative case is tailored specifically for the iPhone 16 Pro and iPhone 16 Pro Max, offering users not just protection but also a unique sensory...

Continue Reading
The Impact of Economic Changes on Small Businesses

Updated Category Business Views 679

The impacts of economic change upon the small businesses have always been a subject of discussion because they determine the further development, income, and stability of the company. Whether dealing with uneven interest rates or changes in consumer behaviors, every shift in the economies' landscape comes with some risks and rewards. By observing the economic changes and...

Continue Reading
NANO Nuclear Energy Investors: Important Class Action Notice

Updated Category News Views 56

Important Update for NANO Nuclear Energy Investors Investors in NANO Nano Nuclear Energy Inc. (NASDAQ: NNE) should be aware of a significant class action lawsuit recently filed in the U.S. District Court. The action targets those who acquired NNE securities, particularly during the specified Class Period. Details of the Class Action This lawsuit has been initiated on...

Continue Reading
Understanding Crimson Tide Plc's Recent Market Disclosure Update

Updated Category News Views 296

Market Position Disclosure for Crimson Tide Plc Crimson Tide Plc, known for its innovative approaches in the mobile technology sector, has made a significant market position disclosure, highlighting details critical for investors and stakeholders. Such disclosures are essential as they provide insight into the company's integrity in maintaining transparency during trading...

Continue Reading